EMIT: Establishment of Molecular profiling for Individual Treatment decisions in Early Breast Cancer. PI: Bjørn Naume.

Inclusion criteria

  1. Written informed consent (informed consent document to be approved by the Independent Ethics Committee [IEC]) obtained prior to any study-specific procedure
  2. Female or male ≥18 years of age
  3. Able to comply with the protocol
  4. Primary surgery completed
  5. Histologically confirmed adenocarcinoma of the breast ≤ 5.0 cm in size (pT1-2) without metastasis to regional lymph nodes (pN0)
  6. Primary tumor concluded as ER positive (> 1%) HER2 negative

Exclusion criteria

  1. Stage IV (metastatic disease).
  2. Previous treatment for localized breast cancer
  3. HER2 positive
  4. As ER and PgR negativity (or <1% expression).
  5. Other concomitant or earlier carcinoma less than five years prior to the breast cancer diagnosis, exept for BCC and in situ cervix cancer
  6. Treatment with any investigational drug. Participation in observational-, diet- or physical activity intervention trials is allowed.

Evidence of any other disease or condition that by the investigator is considered to impede follow up of the patients.